British Columbia Investment Management’s NovoCure NVCR Stock Holding History

British Columbia Investment Management’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-8,570	Closed	-$356K	–	814
2023 Q2	$356K	Buy	8,570 +267	+3%	+$16.6K	﹤0.01%	790
2023 Q1	$499K	Hold	8,303	–	–	0.01%	766
2022 Q4	$609K	Sell	8,303 -907	-10%	-$68.2K	0.01%	738
2022 Q3	$700K	Sell	9,210 -1,592	-15%	-$124K	0.01%	724
2022 Q2	$751K	Sell	10,802 -3,623	-25%	-$273K	0.01%	740
2022 Q1	$1.2M	Sell	14,425 -1,911	-12%	-$141K	0.01%	758
2021 Q4	$1.23M	Sell	16,336 -895	-5%	-$89.8K	0.01%	782
2021 Q3	$2M	Buy	17,231 +204	+1%	+$30.8K	0.01%	694
2021 Q2	$3.78M	Buy	17,027 +2,865	+20%	+$557K	0.02%	527
2021 Q1	$1.87M	Sell	14,162 -353	-2%	-$55.8K	0.01%	680
2020 Q4	$2.51M	Buy	+14,515	New	+$1.99M	0.02%	585

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

British Columbia Investment Management's NVCR Position: Q3 2023 in Review

British Columbia Investment Management sold out of NovoCure (NVCR) in Q3 2023, closing a stake of 8,570 shares — an estimated $356K sold.

British Columbia Investment Management first reported a position in NVCR in Q4 2020 and held it in 11 quarters. The position peaked at $3.78M in Q2 2021. 227 funds tracked by Wall St. Rank hold NVCR as of Q3 2023.

British Columbia Investment Management reported no remaining NovoCure position as of Q3 2023 after selling out during the quarter.
British Columbia Investment Management sold 8,570 NovoCure shares in Q3 2023, an estimated $356K.
British Columbia Investment Management first reported a position in NovoCure in Q4 2020 and held it in 11 quarters.
British Columbia Investment Management's NovoCure position peaked at $3.78M in Q2 2021.
227 funds tracked by Wall St. Rank held NovoCure as of Q3 2023.

Based on British Columbia Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.